Darzalex Faspro

A combination of daratumumab and hyaluronidase used alone or with other drugs to treat adults with multiple myeloma. It is used in patients whose cancer is newly diagnosed and who cannot be treated with an autologous stem cell transplant. Darzalex Faspro is also used in patients whose cancer came back or did not get better after treatment with one or more anticancer therapies. It is also being studied in the treatment of other types of cancer. Daratumumab binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Hyaluronidase allows daratumumab to be given by injection under the skin. Darzalex Faspro can be given in less time than daratumumab alone, which is given as an infusion. Also called daratumumab and hyaluronidase.